NCT06058000

A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

A Phase 2, Randomized, Double-blind,Placebo Controlled, Parallel Group Study to Assess Efficacy, Safety, and Pharmacokinetics (PK) of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess efficacy, safety, and pharmacokinetics (PK) of QLM3003 Ointment in participants with mild or moderate atopic dermatitis.

Detailed description

This study is a Phase 2, randomized, double-blind,placebo controlled, parallel group study to assess efficacy, safety, and pharmacokinetics (PK) of QLM3003 Ointment in participants with mild or moderate atopic dermatitis.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	1.5% QLM3003	QLM3003 topical cream
DRUG	2% QLM3003	QLM3003 topical cream
DRUG	Vehicle (Placebo)	Vehicle topical cream

Timeline

• Start date: 2023-11-13
• Primary completion: 2024-09-02
• Completion: 2024-09-30
• First posted: 2023-09-28
• Last updated: 2025-03-12

Locations

2 sites across 1 country: China